Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04450329
Recruitment Status : Active, not recruiting
First Posted : June 29, 2020
Last Update Posted : May 3, 2021
Information provided by (Responsible Party):
Samsung Bioepis Co., Ltd.

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : April 15, 2021
Estimated Study Completion Date : March 24, 2022